Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJIB89)

Drug Name

Remetinostat Drug Info

Synonyms

UNII-37NT056AT4; 946150-57-8; Methylparaben suberohydroxamic acid phenyl ester; 37NT056AT4; Remetinostat [USAN]; Remetinostat (USAN/INN); CHEMBL3707219; SCHEMBL12682510; DTXSID20647779; NSC748492; Benzoic acid, 4-((8-(hydroxyamino)-1,8-dioxooctyl)oxy)-, methyl ester; NSC-748492; D10977; methyl 4-[8-(hydroxyamino)-8-oxooctanoyl]oxybenzoate; Methyl 4-{[8-(hydroxyamino)-8-oxooctanoyl]oxy}benzoate; Benzoic acid,8-dioxooctyl]oxy]-, methyl ester (MP-shape)

Indication

Disease Entry	ICD 11	Status	REF
Basal cell carcinoma	2C32	Phase 2	[1]
Cutaneous T-cell lymphoma	2B01	Phase 2	[2]

Cross-matching ID

PubChem CID: 24875489
CAS Number: CAS 946150-57-8
TTD Drug ID: DMJIB89

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Histone deacetylase (HDAC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[3]
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[4]
HBI-8000	DMDWYUN	Non-small-cell lung cancer	2C25.Y	Registered	[2]
ITF2357	DMFZBNE	Duchenne dystrophy	8C70	Phase 3	[5]
Pracinostat	DMTD7AB	Acute myeloid leukaemia	2A60	Phase 3	[6]
NVP-LAQ824	DM8JWNA	Mood disorder	6A60-6E23	Phase 3	[7]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[2]
CMS-024-02	DMC4X7L	Solid tumour/cancer	2A00-2F9Z	Phase 3	[8]
Abexinostat	DM91LGU	Follicular lymphoma	2A80	Phase 3	[9]
PDX-101	DM6OC53	Plasma cell myeloma	2A83.1	Phase 2	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase (HDAC)	TTBH0VX	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
4	Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
7	Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
8	US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
9	Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
10	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.